Clinical practice guidelines for intraoperative cell salvage in patients with malignant tumors
Journal Title: Chinese Journal of Blood Transfusion - Year 2025, Vol 38, Issue 2
Abstract
Intraoperative cell salvage (IOCS) has been widely applied as an important blood conservation measure in surgical operations. However, there is currently a lack of clinical practice guidelines for the implementation of IOCS in patients with malignant tumors. This report aims to provide clinicians with recommendations on the use of IOCS in patients with malignant tumors based on the review and assessment of the existed evidence. Data were derived from databases such as PubMed, Embase, the Cochrane Library and Wanfang. The guideline development team formulated recommendations based on the quality of evidence, balance of benefits and harms, patient preferences, and health economic assessments. This study constructed seven major clinical questions. The main conclusions of this guideline are as follows: 1) Compared with no perioperative allogeneic blood transfusion (NPABT), perioperative allogeneic blood transfusion (PABT) leads to a more unfavorable prognosis in cancer patients (Recommended); 2) Compared with the transfusion of allogeneic blood or no transfusion, IOCS does not lead to a more unfavorable prognosis in cancer patients (Recommended); 3) The implementation of IOCS in cancer patients is economically feasible (Recommended); 4) Leukocyte depletion filters (LDF) should be used when implementing IOCS in cancer patients (Strongly Recommended); 5) Irradiation treatment of autologous blood to be reinfused can be used when implementing IOCS in cancer patients (Recommended); 6) A careful assessment of the condition of cancer patients (meeting indications and excluding contraindications) should be conducted before implementing IOCS (Strongly Recommended); 7) Informed consent from cancer patients should be obtained when implementing IOCS, with a thorough pre-assessment of the patient's condition and the likelihood of blood loss, adherence to standardized internally audited management procedures, meeting corresponding conditions, and obtaining corresponding qualifications (Recommended). In brief, current evidence indicates that IOCS can be implemented for some malignant tumor patients who need allogeneic blood transfusion after physician full evaluation, and LDF or irradiation should be used during the implementation process.
Authors and Affiliations
Changtai ZHU, Ling LI, Zhiqiang LI, Xinjian WAN, Shiyao CHEN, Jian PAN, Yi ZHANG, Xiang REN, Kun HAN, Feng ZOU, Aiqing WEN, Ruiming RONG, Rong XIA, Baohua QIAN, Xin MA
Keywords
Related Articles
- EP ID EP760097
- DOI 10.13303/j.cjbt.issn.1004-549x.2025.02.001
- Views 23
- Downloads 0
Correlation between unexpected antibody types and transfusion efficacy in patients with autoimmune hemolytic anemia (AIHA)
Objective To analyze the antibody types of autoimmune hemolytic anemia(AIHA) patients in Panyu district, Guangzhou and track the therapeutic effect of blood transfusion, so as to provide reference for clinical transfusio...
Health economics evaluation of the cost and effectiveness of gray zone setting in blood ELISA screening
Objective To analyze the cost-effectiveness of ELISA grey area strategy through establishing the health economics model. Methods The serological grey area strategy evaluation model was composed of screening strategy subd...
Distribution frequencies of KIR genes among the Korean, Manchu and Han ethnic groups in Jilin Province
Objective To provide foundational data for exploring the association between KIR genes and diseases by analyzing the frequency and polymorphism of killer-cell immunoglobulin-like receptor (KIR) genes in Han, Manchu and K...
Analysis of HLA-Ⅰ antibody specificity and estimation of antigen immunogenicity: 96 patients recieved genotype-matched platelet transfusions
Objective To analyze the specificity of HLA class-Ⅰ antibody in the patients received HLA-matched platelet transfusions and estimate the relative immunogenicity of HLA-Ⅰ antigens. Methods The samples from 96 patients who...
Characteristics of tumor patients with anti-P1 antibody: a retrospective study
Objective To evaluate the detection and distribution characteristics of anti-P1 in tumor patients, so as to aid in blood screening and transfusion safety. Methods The clinical data of 112 658 tumor patients who underwent...